Statistical models to predict clinical outcomes with anakinra vs. tocilizumab treatments for severe pneumonia in COVID19 patients

Eur J Intern Med. 2023 Jun:112:118-120. doi: 10.1016/j.ejim.2023.01.024. Epub 2023 Feb 6.

Authors

Stefania Piconi¹, Silvia Pontiggia², Marco Franzetti², Francesco Branda³, Davide Tosi⁴

Affiliations

¹ Infectious Diseases Unit, A. Manzoni Hospital, Via dell'Eremo 9, Lecco 23900, Italy. Electronic address: [email protected].
² Infectious Diseases Unit, A. Manzoni Hospital, Via dell'Eremo 9, Lecco 23900, Italy.
³ University of Calabria, Rende, (CS), Italy.
⁴ University of Insubria, Varese, (VA), Italy.

No abstract available

Keywords: Acute respiratory distress syndrome; Anakinra; COVID-19; Mortality; Tocilizumab.

Publication types

Letter
Comment

MeSH terms

COVID-19 Drug Treatment
COVID-19*
Humans
Interleukin 1 Receptor Antagonist Protein / therapeutic use
Models, Statistical
Pneumonia* / drug therapy
Treatment Outcome

Substances

Interleukin 1 Receptor Antagonist Protein
tocilizumab